Skip to main content
SpringerLink
Log in

Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

The purpose of this study is to characterize the involvement of hepato-biliary transport and cytochrome-P450 (CYP)-mediated metabolism in the disposition of glyburide and predict its pharmacokinetic variability due to drug interactions and genetic variations. Comprehensive in vitro studies suggested that glyburide is a highly permeable drug with substrate affinity to multiple efflux pumps and to organic anion transporting polypeptide (OATP)1B1 and OATP2B1. Active hepatic uptake was found to be significantly higher than the passive uptake clearance (15.8 versus 5.3 μL/min/106-hepatocytes), using the sandwich-cultured hepatocyte model. In vitro, glyburide is metabolized (intrinsic clearance, 52.9 μL/min/mg-microsomal protein) by CYP3A4, CYP2C9, and CYP2C8 with fraction metabolism of 0.53, 0.36, and 0.11, respectively. Using these in vitro data, physiologically based pharmacokinetic models, assuming rapid-equilibrium between blood and liver compartments or permeability-limited hepatic disposition, were built to describe pharmacokinetics and evaluate drug interactions. Permeability-limited model successfully predicted glyburide interactions with rifampicin and other perpetrator drugs. Conversely, model assuming rapid-equilibrium mispredicted glyburide interactions, overall, suggesting hepatic uptake as the primary rate-determining process in the systemic clearance of glyburide. Further modeling and simulations indicated that the impairment of CYP2C9 function has a minimal effect on the systemic exposure, implying discrepancy in the contribution of CYP2C9 to glyburide clearance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Rydberg T, Jonsson A, Melander A. Comparison of the kinetics of glyburide and its active metabolites in humans. J Clin Pharm Ther. 1995;20(5):283–95.

    Article  CAS  PubMed  Google Scholar 

  2. Zharikova OL, Ravindran S, Nanovskaya TN, Hill RA, Hankins GD, Ahmed MS. Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon. Biochem Pharmacol. 2007;73(12):2012–9.

    Article  CAS  PubMed  Google Scholar 

  3. Ravindran S, Zharikova OL, Hill RA, Nanovskaya TN, Hankins GD, Ahmed MS. Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem Pharmacol. 2006;72(12):1730–7.

    Article  CAS  PubMed  Google Scholar 

  4. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care. 1994;17(9):1026–30.

    Article  CAS  PubMed  Google Scholar 

  5. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72(3):326–32.

    Article  CAS  PubMed  Google Scholar 

  6. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002;71(4):286–96.

    Article  CAS  PubMed  Google Scholar 

  7. Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther. 2005;78(4):370–7.

    Article  CAS  PubMed  Google Scholar 

  8. Ieiri I, Fukae M, Maeda K, Ando Y, Kimura M, Hirota T, et al. Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. Int J Clin Pharmacol Ther. 2012;50(10):689–700.

    Article  CAS  PubMed  Google Scholar 

  9. Zharikova OL, Fokina VM, Nanovskaya TN, Hill RA, Mattison DR, Hankins GD, et al. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol. 2009;78(12):1483–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Zhou L, Naraharisetti SB, Liu L, Wang H, Lin YS, Isoherranen N, et al. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos. 2010;31(4):228–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica Fate Foreign Compd Biol Syst. 2004;34(5):415–27.

    Article  CAS  Google Scholar 

  12. Koenen A, Kock K, Keiser M, Siegmund W, Kroemer HK, Grube M. Steroid hormones specifically modify the activity of organic anion transporting polypeptides. Eur J Pharm Sci. 2012;47(4):774–80.

    Article  CAS  PubMed  Google Scholar 

  13. Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85(1):78–85.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Appel S, Rufenacht T, Kalafsky G, Tetzloff W, Kallay Z, Hitzenberger G, et al. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol. 1995;76(2):29A–32A.

    Article  CAS  PubMed  Google Scholar 

  15. Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol. 2007;63(6):732–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Semple CG, Omile C, Buchanan KD, Beastall GH, Paterson KR. Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol. 1986;22(2):187–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Fleishaker JC, Phillips JP. Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers. J Clin Pharmacol. 1991;31(3):259–62.

    Article  CAS  PubMed  Google Scholar 

  18. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther. 2011;90(4):575–81.

    Article  CAS  PubMed  Google Scholar 

  19. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug–drug interactions of repaglinide. Pharm Res. 2013;30(4):1188–99.

    Article  CAS  PubMed  Google Scholar 

  20. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81(2):194–204.

    Article  CAS  PubMed  Google Scholar 

  21. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819–50.

    Article  CAS  PubMed  Google Scholar 

  22. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36(1):164–72.

    Article  CAS  PubMed  Google Scholar 

  23. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther. 2001;69(6):400–6.

    Article  CAS  PubMed  Google Scholar 

  24. Huang SM, Rowland M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther. 2012;91(3):542–9.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos. 2009;37(8):1587–97.

    Article  CAS  PubMed  Google Scholar 

  26. Greupink R, Schreurs M, Benne MS, Huisman MT, Russel FG. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug–drug-interactions. Eur J Pharm Sci. 2013;49(5):819–28.

    Article  CAS  PubMed  Google Scholar 

  27. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol. 2013.

  28. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004;32(6):647–60.

    Article  CAS  PubMed  Google Scholar 

  29. Adachi Y, Suzuki H, Sugiyama Y. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm Res. 2003;20(8):1163–9.

    Article  CAS  PubMed  Google Scholar 

  30. Kalgutkar AS, Chen D, Varma MV, Feng B, Terra SG, Scialis RJ, et al. Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha. Xenobiotica Fate Foreign Compd Biol Syst. 2013;43(11):963–72.

    Article  CAS  Google Scholar 

  31. Bi YA, Kazolias D, Duignan DB. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos. 2006;34(9):1658–65.

    Article  CAS  PubMed  Google Scholar 

  32. Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36(7):1385–405.

    Article  CAS  PubMed  Google Scholar 

  33. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53(3):1098–108.

    Article  CAS  PubMed  Google Scholar 

  34. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.

    Article  CAS  PubMed  Google Scholar 

  35. Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, et al. A mechanistic framework for in vitro–in vivo extrapolation of liver membrane transporters: prediction of drug–drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet. 2014;53(1):73–87.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug–drug interactions. Pharm Res. 2012;29(10):2860–73.

    Article  CAS  PubMed  Google Scholar 

  37. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, et al. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm. 2012;9(12):3535–42.

    Article  CAS  PubMed  Google Scholar 

  38. Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, et al. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos. 2013;41(5):966–74.

    Article  CAS  PubMed  Google Scholar 

  39. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34(7):1229–36.

    Article  CAS  PubMed  Google Scholar 

  40. Almond LM, Rowland-Yeo K, Howgate EM, Dickinson GL, Tucker GT, Rostami-Hodjegan A. Prediction of the oral clearance of tolbutamide in individuals with different CYP2C9 genotypes using in vitro enzyme kinetic data. Drug Metab Rev. 2006;38:S209–10.

    Article  Google Scholar 

  41. Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br J Clin Pharmacol. 2007;64(1):14–26.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Kleist P, Ehrlich A, Suzuki Y, Timmer W, Wetzelsberger N, Lucker PW, et al. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol. 1997;53(2):149–52.

    Article  CAS  PubMed  Google Scholar 

  43. Neugebauer G, Betzien G, Hrstka V, Kaufmann B, von Mollendorff E, Abshagen U. Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). Int J Clin Pharmacol Ther Toxicol. 1985;23(9):453–60.

    CAS  PubMed  Google Scholar 

  44. Liu L, Pang KS. The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos. 2005;33(1):1–9.

    Article  PubMed  Google Scholar 

  45. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27(5):425–46.

    Article  CAS  PubMed  Google Scholar 

  46. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007–17.

    Article  CAS  PubMed  Google Scholar 

  47. Menochet K, Kenworthy KE, Houston JB, Galetin A. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos. 2012;40(9):1744–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652–62.

    Article  CAS  PubMed  Google Scholar 

  49. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, et al. Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol. 2013;9(4):459–72.

    Article  CAS  PubMed  Google Scholar 

  50. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther. 2013;94(1):64–79.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. USFDA. Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. Center for Drug Evaluation and Research (CDER). 2012.

  52. Camenisch G, Umehara K. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug interactions. Biopharm Drug Dispos. 2012;33(4):179–94.

    Article  CAS  PubMed  Google Scholar 

  53. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26(9):2039–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581–7.

    Article  CAS  PubMed  Google Scholar 

  55. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000;157(5):1575–80.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan RY. Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. Drug Metabol Drug Interact. 2003;19(4):287–95.

    Article  CAS  PubMed  Google Scholar 

  57. Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008;47(10):669–80.

    Article  CAS  PubMed  Google Scholar 

  58. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 “pie”. Drug Metab Dispos. 2006;34(5):880–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Wang R, Chen K, Wen SY, Li J, Wang SQ. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther. 2005;78(1):90–2.

    Article  CAS  PubMed  Google Scholar 

  60. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (−)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther. 2003;74(2):186–94.

    Article  CAS  PubMed  Google Scholar 

  61. Choi CI, Kim MJ, Chung EK, Lee HI, Jang CG, Bae JW, et al. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol. 2012;68(2):149–54.

    Article  CAS  PubMed  Google Scholar 

  62. Cheng Y, Wang G, Zhang W, Fan L, Chen Y, Zhou HH. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur J Clin Pharmacol. 2013;69(3):407–13.

    Article  CAS  PubMed  Google Scholar 

  63. Yoshida K, Maeda K, Sugiyama Y. Transporter-mediated drug–drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther. 2012;91(6):1053–64.

    Article  CAS  PubMed  Google Scholar 

  64. Toda T, Eliasson E, Ask B, Inotsume N, Rane A. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009;105(5):327–32.

    Article  CAS  PubMed  Google Scholar 

  65. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000;56(3):225–9.

    Article  CAS  PubMed  Google Scholar 

  66. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46(1):49–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 2010;38(2):215–22.

    Article  CAS  PubMed  Google Scholar 

  68. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

All authors are full-time employees of Pfizer Inc., at the time of this study. The authors have no conflicts of interest that are directly relevant to this study.

Author information

Authors and Affiliations

  1. Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc, Groton, Connecticut, USA

    Manthena V. S. Varma, Renato J. Scialis, Jian Lin, Yi-An Bi, Charles J. Rotter, Theunis C. Goosen & Xin Yang

Authors
  1. Manthena V. S. Varma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renato J. Scialis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi-An Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles J. Rotter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Theunis C. Goosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manthena V. S. Varma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varma, M.V.S., Scialis, R.J., Lin, J. et al. Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide. AAPS J 16, 736–748 (2014). https://doi.org/10.1208/s12248-014-9614-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-014-9614-7

KEY WORDS

Search

Navigation